theMednetRegister

Gastroenterology

Diabetes   

Questions discussed in this category

How many days prior to elective major surgery do you recommend holding oral GLP 1 R agonist therapy?
4 Answers available
Do you avoid the use of GLP-1 R agonist therapy for treatment of obesity in patients with known gastroparesis?
1 Answer available
Do 5HT4 agonists such as Metoclopramide actually lead to improvement in symptoms for patients with diabetes related gastroparesis?
1 Answer available
When and how should we be stopping GLP-1 Receptor Agonist/Dual Agonist therapy?
1 Answer available
Can rapid weight loss following GLP1 R agonist therapy lead to postprandial hypoglycemia and if so, what are the treatment options outside of dietary modifications?
1 Answer available
Do you recommend the use of SGLT2 inhibitors to reduce the risk of liver cirrhosis in patients with Type 2 diabetes mellitus?
1 Answer available
Do you recommend routinely monitoring pancreatic markers such as amylase and lipase while receiving GLP1 R agonist or dual agonist therapies to determine their risk of pancreatitis?
2 Answers available
Is there a role for use of GLP1 R agonist or dual agonist therapy for management of post bariatric hypoglycemia and dumping syndrome?
1 Answer available
How do you counsel patients on semaglutide or tirzepatide in light of potential cancer risks?
Do you avoid using these agents only in patients with history of medullary thyroid cancer or pancreatic cancer? Are there other cancer risks we should...
1 Answer available
How do you counsel patients on the use of compounded weight loss medications?
3 Answers available


Papers discussed in this category

BMC endocrine disorders, 2024 Nov 18
Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis.
International urology and nephrology, 2024 Nov 04
Effect of GLP-1 receptor agonists on prostate cancer risk reduction: a systematic review and meta-analysis.
Cancers, 2024 Sep 22
Risk of Esophageal and Gastric Cancer in Patients with Type 2 Diabetes Receiving Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A National Analysis.
The New England journal of medicine, 2015-07-02
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Annals of translational medicine, 2021 Sep
Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data.
International journal of molecular sciences, 2022 Mar 13
SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection.
The New England journal of medicine, 2025 May 11
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery, 2024 Oct 29
Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period.

Related Topics in Gastroenterology

Copyright © 2025 theMednet
All Rights Reserved.